A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

Bibliographic Details
Main Authors:	Papadopoulos, Kyriakos P., Burris, Howard A., Gordon, Michael, Lee, Peter, Sausville, Edward A., Rosen, Peter J., Patnaik, Amita, Cutler, Richard E., Wang, Zhengping, Lee, Susan, Jones, Suzanne F., Infante, Jeffery R.
Format:	Online
Language:	English
Published:	Springer Berlin Heidelberg 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784064/

Similar Items

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
by: Kyriakos P. Papadopoulos, et al.
Published: (2018-08-01)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
by: Jurczyszyn, Artur, et al.
Published: (2014)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
by: Rosenthal, A, et al.
Published: (2016)

Targeted treatments for multiple myeloma: specific role of carfilzomib
by: Sugumar, Dhivya, et al.
Published: (2015)

Thrombotic microangiopathy during carfilzomib use: case series in Singapore
by: Chen, Y, et al.
Published: (2016)

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
by: Badros, A Z, et al.
Published: (2013)

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
by: Lee, Susan J., et al.
Published: (2016)

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
by: Jain, Salvia, et al.
Published: (2011)

Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma
by: Hu, Bo, et al.
Published: (2013)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
by: Nooka, Ajay, et al.
Published: (2013)

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
by: Fostier, Karel, et al.
Published: (2012)

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma
by: Gao, Minjie, et al.
Published: (2016)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
by: Atrash, S, et al.
Published: (2015)

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
by: Zhang, Lisa, et al.
Published: (2016)

Mannitol Infusion Within 15 Min of Cross-Clamp Improves Living Donor Kidney Preservation
by: Andrews, Peter M., et al.
Published: (2014)

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
by: Pant, Shubham, et al.
Published: (2013)

Cellular organization by self-organization: mechanisms and models for Min protein dynamics
by: Howard, Martin, et al.
Published: (2005)

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
by: Murakami, H., et al.
Published: (2014)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
by: Kraus, M, et al.
Published: (2013)

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models
by: Crawford, L J, et al.
Published: (2014)

Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
by: Harvey, R Donald
Published: (2014)

Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini
by: Kowalewski, D J, et al.
Published: (2016)

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I
by: Yang, Guang, et al.
Published: (2015)

KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models
by: Riz, Irene, et al.
Published: (2015)

The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5
by: Han, Bo, et al.
Published: (2015)

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2
by: Gao, Lu, et al.
Published: (2015)

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
by: Watanabe, Takashi, et al.
Published: (2016)

Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
by: Hobeika, Liliane, et al.
Published: (2014)

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring
by: Chari, Ajai, et al.
Published: (2014)

Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models
by: Baker, Amanda F, et al.
Published: (2014)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
by: Liu, Liping, et al.
Published: (2016)

MinC, MinD, and MinE Drive Counter-oscillation of Early-Cell-Division Proteins Prior to Escherichia coli Septum Formation
by: Bisicchia, Paola, et al.
Published: (2013)

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
by: Tolcher, Anthony W., et al.
Published: (2013)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
by: Molife, L Rhoda, et al.
Published: (2014)

Infusion of 2.5 meq/min of lactic acid minimally increases CO2 production compared to an isocaloric glucose infusion in healthy anesthetized, mechanically ventilated pigs
by: Zanella, Alberto, et al.
Published: (2013)

Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours.
by: Desoize, B., et al.
Published: (1990)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
by: Wu, Huali, et al.
Published: (2015)

Spanish as the Kana for Taiwan Southern Min
by: Richie, L. C. Chen
Published: (2012)

RM14 min for bridge study
by: UNSPECIFIED,
Published: (2017)

Al-hiyal min manzur islami
by: Nik Zainun
Published: (2004)